Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, gas is a recognised side effect of Wegovy (semaglutide). Clinical trial data and the medicine's official prescribing information both record flatulence and abdominal bloating among the gastrointestinal effects reported by patients. For most people it is mild, tends to cluster around the early weeks of treatment or after a dose increase, and eases as the body adjusts. It is worth knowing what to expect, and equally worth knowing which symptoms deserve more than patience. Wegovy is a prescription-only medicine that a registered prescriber assesses your suitability for before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity to semaglutide 2.4mg or placebo over 68 weeks. Gastrointestinal events were the most commonly reported side effects in the active group, with nausea, diarrhoea and vomiting leading the list. Flatulence and abdominal distension were also recorded, sitting alongside belching and constipation as part of a broader gut-related picture.
The pattern in the trial data is consistent: symptoms spiked around dose increases and then settled. That is not coincidence. GLP-1 receptor agonists like semaglutide slow the rate at which the stomach empties, which is partly how they reduce appetite. The knock-on effect is that gas, fullness and rumbling are more common early on, when the gut is still adapting. Most participants in STEP 1 who reported these effects did not stop treatment because of them.
You can read the full side-effect profile on the NHS semaglutide medicines page, which translates the clinical data into plain language. The picture it paints is: uncomfortable for some, manageable for most, and rarely a reason to stop on its own.
Flatulence is listed explicitly in Wegovy's Summary of Product Characteristics as a known side effect. The frequency category places it in the common-to-uncommon range depending on the reporting convention used, but the patient experience data from trials suggests a meaningful proportion of people notice it at some point, particularly in the first four to eight weeks.
The mechanism is practical rather than mysterious. Slower gastric emptying means food lingers longer in the upper gut. Fermentation by gut bacteria continues in the meantime, and gas is the by-product. Add to that any dietary shifts (eating smaller portions, sometimes less fibre or more protein) and the gut's microbiome takes a little time to recalibrate.
A few things tend to help: eating slowly, avoiding carbonated drinks, keeping meals smaller and more frequent rather than large and infrequent, and giving the body a few weeks before deciding whether the symptom is settling. Our full Wegovy side effects guide covers the wider range of gut symptoms in more depth. Belching is a related experience that some patients find more bothersome than flatulence; if that resonates, the burping and Wegovy page is worth reading alongside this one.
None of that is to dismiss how annoying it can be. If you started Wegovy hoping no one in your household would notice, gas is the sort of side effect that makes that ambition complicated. That frustration is reasonable, and it is worth raising with your prescriber rather than quietly tolerating it.
Most gut symptoms on Wegovy are a nuisance. A smaller group are a signal.
In January 2026 the MHRA issued a Drug Safety Update specifically about GLP-1 medicines, highlighting acute pancreatitis as an infrequent but serious risk. The symptom to watch for is severe stomach pain that does not pass, particularly if it radiates toward the back, with or without vomiting. That is not gas. That is a reason to stop the injection and seek urgent medical help.
Other symptoms that go beyond the expected adjustment period include signs of gallbladder problems (sudden upper-right abdominal pain, fever, jaundice), severe vomiting or diarrhoea leading to dehydration, and any allergic reaction such as swelling of the face, throat, or difficulty breathing. The NHS guidance on semaglutide lists these with clear advice on when to call 111 or go straight to A&E.
If something feels wrong (genuinely wrong, not just uncomfortable) act on that instinct. The broader overview of Wegovy side effects covers the full range of reported reactions, including less common ones.
Suspected side effects, including unexpected gas patterns that worry you, can be reported to the MHRA through the Yellow Card scheme. It exists for exactly this reason, and reports from real patients inform how medicines are monitored after they reach the market.
Gas and bloating sit well within the expected side-effect profile of Wegovy. They are not a sign the medicine is harming you, and they are not a reason to stop without speaking to your prescriber first. At the same time, nobody should feel they have to simply endure them without any discussion.
At nume, our clinical team discusses exactly this kind of thing as part of every consultation. A real clinician reads your answers (not software) and the conversation about side effects is built into the process, not an afterthought. If you are curious about whether Wegovy is right for you, or want to understand more about what treatment involves before committing, the free consultation is the place to start.
Other side effects some patients ask about include hair thinning and headaches, both covered in detail if those questions are on your list too.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.